VANCOUVER, BC / ACCESSWIRE / March 15, 2016 / NetCents Technology Inc. (CSE: NC) (“NetCents” or the “Company“) is proud to announce that it has expanded its global reach; NetCents now accepts consumer deposits from 24 countries, including North America, Brazil, Australia, Western Europe, and Japan.

“Credit card deposits is just the most recent addition to our services, giving users more options and flexibility,” said Clayton Moore, NetCents Founder and CEO. “We provide a service to consumers that is flexible. If you want to transfer funds peer-to-peer, you can do that, if you want to transact digital currency, you can do that, if you want to transfer money via credit card, you can now do that as well. Consumers want flexibility and choice and we give that to them.”

This addition greatly enhances NetCents’ market reach and processing capabilities, allowing users more efficient ways to pay. The integration allows NetCents users to receive deposits from consumers using major credit cards, including: Visa, MasterCard, American Express, and Apple Pay. NetCents offers consumers more options, flexibility, security, and ease of use, all in one place.

“The basic premise behind NetCents is one unified open-source payment platform, combining all mobile and online payment services,” said Robert Meister, Director of Capital Market at NetCents, “in any marketplace, consumers want simplicity of use and that’s what we’re giving them.”

About NetCents

NetCents is an online payments platform, offering consumers and merchants online services for managing electronic payments. NetCents works with its financial partners, mobile operators, exchanges, etc., to streamline the user experience of transacting online. The NetCents technology is integrated into the Automated Clearing House (“ACH”), which ensures our consumer’s security and privacy. This integration allows the Company to accept and transfer deposits from users in 24 countries, enhancing the users online experience, granting them the freedom and convenience to Pay. Your. Way.™

Further information about the Company it is available under its profile on the SEDAR website, www.sedar.com, on the CSE website www.thecse.com, on our website www.netcents.biz or contact Robert Meister, Capital Markets at Ph: 604.676.5248 or email: Robert.meister@net-cents.com.

On Behalf of the Board of Directors

NetCents Technology Inc.

“Clayton Moore”
Clayton Moore, CEO, Founder and Director

NetCents Technology Inc.
Suite 1500, 885 West Georgia Street
Vancouver, British Columbia V6C 3E8

Cautionary Note Regarding Forward Looking Information

This release includes certain statements that may be deemed “forward-looking statements.” All statements in this release, other than statements of historical facts, that address events or developments that the Company expects to occur, are forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects,” “plans,” “anticipates,” “believes,” “intends,” “estimates,” “projects,” “potential” and similar expressions, or that events or conditions “will,” “would,” “may,” “could” or “should” occur. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in the forward-looking statements. Factors that could cause the actual results to differ materially from those in forward-looking statements include regulatory actions, market prices, and continued availability of capital and financing, and general economic, market or business conditions. Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of the Company’s management on the date the statements are made. Except as required by applicable securities laws, the Company undertakes no obligation to update these forward-looking statements in the event that management’s beliefs, estimates or opinions, or other factors, should change.

SOURCE: NetCents Technology Inc.

ReleaseID: 437872

SEATTLE, WA / ACCESSWIRE / March 15, 2016 / There are many different companies active in the medical marijuana industry, but few of them are conducting clinical research trials in accord with the Helsinki Committee Institutional Review Board protocols. Most investors are familiar with GW Pharmaceuticals plc (NASDAQ: GWPH) and its Sativex® cannabinoid medicine for the treatment of multiple sclerosis symptoms and cancer pain indications, but OWC Pharmaceutical Research Corp. (OTCQB: OWCP) is a lesser known company operating in the burgeoning industry.

Based in Israel, an international tech and biotech hub, and the epicenter of medical cannabis research, the OWCP is conducting clinical trials of cannabis-based treatments for multiple myeloma, psoriasis, fibromyalgia, post-traumatic stress disorder and migraines. The team is also working on several proprietary drug delivery mechanisms designed to provide consistent and reliable cannabinoid doses to patients more efficiently than smoking or consuming marijuana edibles.

High Quality Clinical Trials

OWC Pharmaceuticals’ clinical studies are being conducted at the Sheba Academic Medical Center in Tel Hashomer, Israel, in full compliance with Helsinki Committee/IRB conventions. Sheba is one of the leading medical centers in the Middle East, and one of only two facilities in Israel with the U.S. Department of Health and Human Services’ federal-wide assurance designation, which provides it with U.S. federal research grants involving human clinical trials.

The Company’s clinical programs are being spearheaded by Dr. Yehuda Baruch, who headed Israel’s national medical marijuana program from 2003 to 2013. Dr. Baruch’s vast experience in both the regulatory and medical aspects of the cannabis industry have been very instrumental in moving OWCP’s clinical programs forward while ensuring full compliance with the terms established under the IRB-approved protocols.

Initial Focus on Multiple Myeloma

OWC Pharmaceuticals’ most advanced clinical program is targeting multiple myeloma – a form of bone marrow cancer that accounts for 2% of all cancer deaths. In preliminary studies, the Company demonstrated that some combinations of THC and CBD led to the eradication of 100% of myeloma cells in 60% of the cultured cells within 24 to 48 hours of exposure to the cannabinoid formulation. These early stage in-vitro results may be limited, but they demonstrate significant potential within the market.

The Company’s multiple myeloma research is overseen by Dr. Asaf Toker, who now serves as OWCP’s Chief Science Officer. Dr. Toker has extensive industry experience, most recently as CEO of AGAM Group, and Medical Director for Meuhedet Health Services, the third largest health service provider in Israel. Dr. Merav Leiba was also added as Senior Science Advisor and serves as the Head of the Multiple Myeloma Outpatient Clinic and Research Lab at the Sheba Academic Medical Center’s Hematology Institute, where she led the Company’s in-vitro testing.

Additional Clinical Programs

OWC Pharmaceuticals is targeting two other indications alongside its multiple myeloma clinical trials. In psoriasis, the Company has submitted a protocol for a Phase I, double-blind, randomized, placebo-controlled study consisting of multiple escalating doses of cannabinoids to determine the safety, tolerability, and pharmacokinetic profile of medical grade cannabis. OWCP hopes to develop a treatment for the painful skin condition leveraging cannabinoids.

In addition, the Company expects to receive Helsinki Committee approval for a pre-clinical, in-vitro fibromyalgia study during the second quarter of this year. The chronic condition, causing pain throughout the body, affects more than 10 million people in the U.S. and an estimated 3% to 6% of the world’s population. OWCP believes that cannabinoids may be effective in treating the condition and alleviating symptoms for patients with few alternatives.

Other Commercial Activity

OWC Pharmaceuticals operates a consulting division designed to advise medical marijuana businesses around the world. Last year, the Company signed an agreement with MedMar LLC, a U.S. based company with operations in three states, to help them establish a medical cannabis treatment program. The Company will provide MedMar with a variety of services, including defining its product and service offerings, developing operating and training protocols for its staff and management, and ensuring compliance with applicable government regulations.

Also last year, the Company entered into a strategic alliance with Emilia Cosmetics Ltd., one of Israel’s largest private label cosmetic manufacturers, to develop a CBD-infused topical cream which will be used as part of its psoriasis clinical trial. And finally, OWCP is developing tablet and cream-based delivery systems that make cannabinoid consumption and absorption more predictable than conventional medical marijuana delivery methods.

Looking Ahead

There are many different companies operating in the medical marijuana space, ranging from Medical Marijuana Inc. (OTCQB: MJNA) to Cara Therapeutics Inc. (NASDAQ: CARA). OWC Pharmaceuticals differentiates itself from many of its competitors given its practice of conducting IRB-sanctioned clinical trials as it seeks to bring unique indications to market. Further, the Company’s consulting division provides additional near-term revenue to help offset the costs associated with its research and development.

For more information, visit the company’s website at www.owcpharma.com.

Legal Disclaimer

Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Emerging Growth LLC dba TDM Financial, which owns CFN Media, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. Emerging Growth LLC dba TDM Financial, which owns CFN Media, may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. Emerging Growth LLC dba TDM Financial, which owns CFN Media, may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two. For full disclosure please visit: http://www.cannabisfn.com/legal-disclaimer/.

SOURCE: CFN Media

ReleaseID: 437873

SOUTH BOSTON, MA / ACCESSWIRE / March 15, 2016 / A fantastic event of learning how to “Double Your Income with the 1031 Exchange” will be co-hosted by Philip Ganz from Fairway Mortgage and Robert H Guida Esq from Guida Law.

The event will take place April 5^th, 2016 from 10am to noon. Lynne Bagby, CES®, Division Manager of Asset Preservation will be the speaker. Lynn an incredible expert and resource for the 1031 exchange will show you the four basic strategies delayed, improvement, reverse and the personal property.

A delayed exchange is the most popular exchange format, providing investors the flexibility of up to a maximum of 180 days to purchase a replacement property.

The improvement exchange allows an investor to make improvements on a new replacement property using exchange equity. Just like it sounds you can use tax free dollars to build or improve property.

A reverse 1031 exchange represents a tax deferment strategy when for a variety of reasons, the replacement property must be purchased before the relinquished or old property is sold. Careful planning is highly recommended.

Personal property exchange allows investors to exchange either like-kind real or personal property for other like-kind real or personal property. Although the rules for like-kind real estate are fairly broad, the rules to exchange personal property for like-kind or like-class specify that an Exchanger can only receive tax deferral if the sale of personal property is exchanged for the purchase of personal property that falls within the same Product Class or General Asset Class.

The event will be providing CE credits to Realtors but knowledge to everyone. If you are a Realtor, Investor, Media or just have a big dream this event is for you.

For More Information, please visit http://bit.ly/1031exchangeboston

We look forward to seeing you at Fairway Mortgage 380 West Broadway Suite 101 South Boston!

Media Contact:

Fairway Independent Mortgage Corporation
380 West Broadway
Unit 101
South Boston, MA 02127

SOURCE: Fairway Independent Mortgage Corporation

ReleaseID: 437850

NEW YORK, NY / ACCESSWIRE / March 15, 2016 / Moments ago, Trader’s Choice released new research updates concerning several important developing situations including the following equities: Penn Virginia Corp. (OTC: PVAH), OceanaGold Corp. (OTC: OCANF), Infineon Technologies AG (OTC: IFNNY) and Reckitt Benckiser Group Plc (OTC: RBGLY). Trader’s Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.

To access our full PDF Research Packages for free, please visit the links below.

============

Full PDF DOWNLOAD Links

(You may have to copy and paste the links into your browser)

PVAH Research Package: http://www.traders-choice.com/pdf?s=PVAH

OCANF Research Package: http://www.traders-choice.com/pdf?s=OCANF

IFNNY Research Package: http://www.traders-choice.com/pdf?s=IFNNY

RBGLY Research Package: http://www.traders-choice.com/pdf?s=RBGLY

============

Highlights from today’s reports include:

On Monday, March 14, 2016, NASDAQ Composite ended at 4,750.28, up 0.04%, Dow Jones Industrial Average advanced 0.09%, to finish the day at 17,229.13, and the S&P 500 closed at 2,019.64, down 0.13%.

– Penn Virginia Corp.’s stock edged lower by 11.36% to close Monday’s session at USD 0.20. The company’s shares oscillated between USD 0.17 and USD 0.22. The stock recorded a trading volume of 2.69 million shares, which was below its 50-day daily average volume of 3.26 million shares and below its 52-week average volume of 3.54 million shares. Over the last three days Penn Virginia Corp.’s shares have declined by 17.37% and in the past one week the stock has moved down 46.82%. Furthermore, over the last three months the stock has lost 39.06% and in the past six months the shares have shed 75.93%. On a compounded total return basis, the company has returned 274.28% in the past one month. The stock is trading at a price to book ratio of 0.03, compared to its historical PB ratio of 0.70. Additionally, the stock is trading at a price to cash flow ratio of 0.06 and price to sales ratio of 0.04. The stock has a beta of 3.69.

– The stock of OceanaGold Corp. lost 9.72% to close Monday’s session at USD 2.60. The shares of the company moved in the range of USD 2.58 and USD 2.84. A trading volume of 0.29 million shares was recorded, which was lower than its 150-day daily average volume of 2.22 million shares but above its 52-week average volume of 0.06 million shares. Over the last five days OceanaGold Corp.’s shares have declined by 14.19% while in the past one month the stock has gained a momentum of 4.42%. Additionally, over the last three months the stock has advanced 38.00% and in the past six months the shares have registered a gain of 52.65%. OceanaGold Corp. has a current dividend yield of 1.42%. The stock is trading at a price to book ratio of 1.35 compared to its historical PB ratio of 1.01. Further, the stock is trading at a price to cash flow ratio of 8.23 and price to sales ratio of 3.09. The stock has a beta of 2.39.

– Infineon Technologies AG’s stock increased by 0.38% to close Monday’s session at USD 13.32. The company’s shares fluctuated in the range of USD 13.28 and USD 13.39. A total of 0.10 million shares exchanged hands, which was lesser than its 50-day daily average volume of 0.16 million shares and its 52-week average volume of 0.17 million shares. Over the last three days Infineon Technologies AG’s shares have advanced 6.90% and in the past one week the stock has moved up 5.13%. Furthermore, over the last three months the stock has lost 7.63% while in the past six months the shares have picked up 19.25%. The company has returned 21.46% in the last half year, on a compounded total return basis. Infineon Technologies AG has a current dividend yield of 1.67%. Further, the company is trading at a price to earnings ratio of 20.46, compared to its historical PE ratio of 18.37.

– Reckitt Benckiser Group PLC’s stock added 0.76% to close Monday’s session at USD 19.24. The share price vacillated between USD 19.00 and USD 19.33. The stock recorded a trading volume of 0.06 million shares, which was below its 50-day daily average volume of 1.27 million shares and its 52-week average volume of 0.22 million shares. Over the last five days Reckitt Benckiser Group PLC’s shares have advanced 3.30% while in the past one month the stock has gained a momentum of 10.89%. In addition, over the last three months the stock has gained 9.02% and year to date the shares have picked up 2.69%. The company has returned 10.03% in the past one month and 12.32% in the past one year, on a compounded total return basis. The stock is trading at a price to book ratio of 6.85, compared to its historical PB ratio of 6.49. Additionally, the stock is trading at a price to cash flow ratio of 23.37 and price to sales ratio of 5.28. The stock has a beta of 0.65.

About Trader’s Choice:

Trader’s Choice (“TC”) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. TC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

TC has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third party research service company (the “Reviewer”). The Reviewer has reviewed and revised the content, as necessary, based on sound investment judgment and publicly available information which is believed to be reliable. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer (collectively referred to as the “Production Team”) in any way. The Production Team is compensated on a fixed monthly basis and do not hold any positions of interest in any of the securities mentioned herein. The information in this release has been sourced from a third party data base.

NO WARRANTY

TC, the Author and the Reviewer (collectively referred to as the “Publishers”) are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by the Publishers whatsoever for any direct, indirect or consequential loss arising from the use of this document. The Publishers expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, the Publishers do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither TC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.traders-choice.com/.

RESTRICTIONS

TC is not available to residents of Belarus, Cuba, Canada, Iran, North Korea, Sudan, Syria or Somalia.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:
E-mail: press (at) traders-choice.com

SOURCE: Trader’s Choice

ReleaseID: 437869

NEW YORK, NY / ACCESSWIRE / March 15, 2016 / Moments ago, Trader’s Choice released new research updates concerning several important developing situations including the following equities: National Energy Services Inc. (OTC: NESV), MedeFile International Inc. (OTC: MDFI), TrueGold Mining Inc. (OTC: RVREF) and Solarwindow Technologies Inc. (OTC: WNDW). Trader’s Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.

To access our full PDF Research Packages for free, please visit the links below.

============

Full PDF DOWNLOAD Links

(You may have to copy and paste the links into your browser)

NESV Research Package: http://www.traders-choice.com/pdf?s=NESV

MDFI Research Package: http://www.traders-choice.com/pdf?s=MDFI

RVREF Research Package: http://www.traders-choice.com/pdf?s=RVREF

WNDW Research Package: http://www.traders-choice.com/pdf?s=WNDW

============

Highlights from today’s reports include:

On Monday, March 14, 2016, NASDAQ Composite ended at 4,750.28, up 0.04%, Dow Jones Industrial Average advanced 0.09%, to finish the day at 17,229.13, and the S&P 500 closed at 2019.64, down 0.13%.

– National Energy Services Inc.’s stock edged higher by 18.18% to close Monday’s session at USD 0.0013. The company’s shares oscillated between USD 0.0010 and USD 0.0013. The stock recorded a trading volume of 3.67 million shares, which was below its 50-day daily average volume of 7.36 million shares and above its 52-week average volume of 2.11 million shares. Over the last three days National Energy Services Inc.’s shares have declined by 18.75% and in the past one week the stock has moved down 27.78%. Furthermore, over the last three months the stock has lost 67.50% and in the past six months the shares have shed 96.84%. On a compounded total return basis, the company has returned 30.00% in the past one month. The 52 week trading range of the stock is between USD 0.0006 and USD 1.50.

– The stock of MedeFile International Inc. lost 7.88% to close Monday’s session at USD 0.52. The shares of the company moved in the range of USD 0.51 and USD 0.62. A trading volume of 0.29 million shares was recorded, which was greater than its 150-day daily average volume of 0.06 million shares and was above its 52-week average volume of 0.04 million shares. Over the last five days MedeFile International Inc.’s shares have declined by 24.98% and in the past one month the stock has lost 67.21%. Additionally, over the last three months the stock has declined 20.45% while in the past six months the shares have registered a profit of 2.94%. Further, the stock is trading at a price to sales ratio of 328.26 and at a price to book ratio of 47.49.

– TrueGold Mining Inc.’s stock decreased by 5.42% to close Monday’s session at USD 0.33. The company’s shares fluctuated in the range of USD 0.33 and USD 0.34. A total of 0.13 million shares exchanged hands, which was lesser than its 50-day daily average volume of 1.27 million shares and was above its 52-week average volume of 0.09 million shares. Over the last three days TrueGold Mining Inc.’s shares have declined by 4.68% and in the past one week the stock has moved down 8.33%. Furthermore, over the last three months the stock has gained 79.59% and in the past six months the shares have picked up 137.84%. The company has returned 90.42% in the past three months and 136.56% in the last half year, on a compounded total return basis. The 52 week trading range of the stock is between USD 0.11 and USD 0.38.

– Solarwindow Technologies Inc.’s stock slipped by 4.09% to close Monday’s session at USD 3.75. The share price vacillated between USD 3.63 and USD 3.88. The stock recorded a trading volume of 0.06 million shares, which was below its 50-day daily average volume of 0.12 million shares and below its 52-week average volume of 0.13 million shares. Over the last five days Solarwindow Technologies Inc.’s shares have declined by 7.18% while in the past one month the stock has gained a momentum of 16.10%. In addition, over the last three months the stock has gained 6.53% and year to date the shares have picked up 15.74%. The company has returned 20.97% in the past one month and 90.36% in the past one year, on a compounded total return basis. Moreover, the stock is trading above its 50-day moving average and 200-day moving average of USD 3.36 and USD 3.00, respectively.

About Trader’s Choice:

Trader’s Choice (“TC”) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. TC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

TC has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third party research service company (the “Reviewer”). The Reviewer has reviewed and revised the content, as necessary, based on sound investment judgment and publicly available information which is believed to be reliable. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer (collectively referred to as the “Production Team”) in any way. The Production Team is compensated on a fixed monthly basis and do not hold any positions of interest in any of the securities mentioned herein. The information in this release has been sourced from a third party data base.

NO WARRANTY

TC, the Author and the Reviewer (collectively referred to as the “Publishers”) are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by the Publishers whatsoever for any direct, indirect or consequential loss arising from the use of this document. The Publishers expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, the Publishers do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither TC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.traders-choice.com/.

RESTRICTIONS

TC is not available to residents of Belarus, Cuba, Canada, Iran, North Korea, Sudan, Syria or Somalia.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:
E-mail: press (at) traders-choice.com

SOURCE: Trader’s Choice

ReleaseID: 437868

TORONTO, ON / ACCESSWIRE / March 15, 2016 / INTELLIGENT CONTENT ENTERPRISES INC. (OTCQB: ICEIF) (“ICE” or the “Company”), announces that its wholly-owned subsidiary Digital Widget Factory Inc. (“DWF”), is launching through its global, multi-lingual online creation, proprietary management and advertising platform, an additional 26 new websites, bringing the total number to 358 sites. The new websites are focused in the areas of Food, Family and Home market segments.

ICE would also like to invite all current and prospective stakeholders to view a video presentation, providing an overview of the Company and its DWF proprietary offerings. The video can be found at: www.intelligentcontententerprises.com and http://www.otcmarkets.com/stock/ICEIF/video-and-presentations

DWF operates an expanding portfolio of websites under the primary URL www.digiwidgy.com that powers user and advertising engagement programs in the US, Canada, Asia, Middle East, Europe, Central and South America in over 50 languages in real-time to desktop, mobile and portable devices.

Through its intelligent content technology, DWF’s platform evaluates user engagement and site follow through and based on those assessments recommends which content channels achieve the popularity standards of a stand-alone DWF site and then recommends their launch to the expanding portfolio of DWF websites. The new sites include topics covering recipes and food related fan sites, baby and parenting, home and garden sites and more.

DWF focuses on high value topics where people around the world can consume content in their native language through DWF’s proprietary technology, enabling content to be published and consumed in a myriad of languages without human intervention and creating significant economies of scale in the online content sector. Advertisers can create opportunities based on both language and location, monetizing across a wide range of demographics, creating revenue opportunities for DWF and themselves through a single platform.

With over 3 billion internet users worldwide, approximately 73% or 2.19 Billion people are engaging online in a language other than English, (Source: Common Sense Advisory). The top 10 languages (English, Chinese, Spanish, Arabic, Portuguese, Japanese, Russian, Malay, French and German) account for 78% of all internet users online today (Source: Internet World Stats).

More than 72% of consumers say that they are likely to purchase online if the experience is in their preferred language (Source: Common Sense Advisory). DWF’s technology provides the ability to localize both language and advertising separately providing solutions that truly engage the user both in their language and their location.

For further information, please contact:

Intelligent Content Enterprises Inc.
Investor Relations: investorrelations@intelligentcontententerprises.com

Certain information regarding the Company in this news release may constitute forward-looking statements under applicable securities laws. The forward-looking information includes, without limitation, projections or estimates made by us and our management in connection with our business operations. Various assumptions were used in drawing the conclusions or making the forecasts and projections contained in the forward-looking information contained in this press release, which assumptions are based on management analysis of historical trends, experience, current conditions and expected future developments pertaining to the Company and the industry in which it operates as well as certain assumptions as specifically outlined in the release above. Forward-looking information is based on current expectations, estimates and projections that involve a number of risks, which could cause actual results to vary and in some instances to differ materially from those anticipated by the Company and described in the forward-looking information contained in this press release. Undue reliance should not be placed on forward-looking information, which is not a guarantee of performance and is subject to a number of risks or uncertainties. Readers are cautioned that the foregoing list of risk factors is not exhaustive. Forward-looking information is based on the estimates and opinions of the Company’s management at the time the information is released and the Company disclaims any intent or obligation to update publicly any such forward-looking information, whether as a result of new information, future events or otherwise, other than as expressly required by applicable securities laws.

SOURCE: Intelligent Content Enterprises Inc.

ReleaseID: 437844

SUNRISE, FL / ACCESSWIRE / March 15, 2016 / U.S. STEM CELL, Inc., a Florida corporation, (f/k/a/ Bioheart, Inc.) (OTCQB: USRM) a leader in the regenerative medicine, cellular therapy industry providing physician based stem cell therapies to human and animal patients as well as a developer of novel autologous cell therapies, is pleased to highlight the following results from operations for the year ending December 31, 2015:

– Current Liabilities (Debt) decreased 28% or $3.1 million, as of December 31, 2015 from $11.1 million to $8.0 million
– Working capital deficit improved 40% for the same time period year-over-year from $10.9 million (10K 2014) to $6.6 million (10K 2015)
– Revenue increased by 8% from $2.06M (10K 2014) to $2.2M (10K 2015)
– Net loss improved 26% from $2.3M in 2014 to $1.7M in 2015 (gain on debt in 2014 of $2.5M as compared to gain of debt of $2.6M in 2015)

“We are very pleased with our continuing year-over-year improvements in operations and balance sheet performance,” stated Mike Tomas, President & CEO of U.S. Stem Cell Inc. “This last year we also completed our new branding campaign and continued to advance our key strategic business initiatives, which are to grow top line revenues, move the company to positive cash flows and to seek out new business opportunities for continued growth. We sincerely thank our shareholders and friends for the long-standing support and we look forward to reporting on our future successes.”

About U.S. Stem Cell, Inc.

US Stem cell, Inc. (formerly Bioheart, Inc.) is an emerging enterprise in the regenerative medicine / cellular therapy industry. We are focused on the discovery, development and commercialization of cell based therapeutics that prevent, treat or cure disease by repairing and replacing damaged or aged tissue, cells and organs and restoring their normal function. We believe that regenerative medicine / cellular therapeutics will play a large role in positively changing the natural history of diseases ultimately, we contend, lessening patient burdens as well as reducing the associated economic impact disease imposes upon modern society.

Our business, which includes three operating divisions (US Stem Cell Training, Vetbiologics and US Stem Cell Clinic) includes the development of proprietary cell therapy products as well as revenue generating physician and patient based regenerative medicine / cell therapy training services, cell collection and cell storage services, the sale of cell collection and treatment kits for humans and animals, and the operation of a cell therapy clinic. Management maintains that revenues and their associated cash in-flows generated from our businesses will, over time, provide funds to support our clinical development activities as they do today for our general business operations. We believe the combination of our own therapeutics pipeline combined with our revenue generating capabilities provides the Company with a unique opportunity for growth and a pathway to profitability.

Forward-Looking Statements: Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as “may,” “will,” “to,”  ”plan,” “expect,” “believe,”  ”anticipate,” “intend,” “could,”  ”would,” “estimate,” or “continue,” or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Also, forward-looking statements represent our management’s beliefs and assumptions only as of the date hereof. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.

The Company is subject to the risks and uncertainties described in its filings with the Securities and Exchange Commission, including the section entitled “Risk Factors” in its Annual Report on Form 10-K for the year ended December 31, 2014, and its Quarterly Reports on Form 10-Q.

Media Contact:

U.S. Stem Cell, Inc.
13794 NW 4th Street, Suite 212
Sunrise, Florida 33325
Phone: 954.835.1500

SOURCE: U.S. Stem Cell, Inc.

ReleaseID: 437871

NEW YORK, NY / ACCESSWIRE / March 15, 2016 / Moments ago, Trader’s Choice released new research updates concerning several important developing situations including the following equities: Amarantus Bioscience Holdings Inc. (OTC: AMBS), Koninklijke KPN NV (OTC: KKPNY), Wolseley PLC (OTC: WOSYY) and Detour Gold Corp. (OTC: DRGDF). Trader’s Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.

To access our full PDF Research Packages for free, please visit the links below.

============

Full PDF DOWNLOAD Links

(You may have to copy and paste the links into your browser)

AMBS Research Package: http://www.traders-choice.com/pdf?s=AMBS

KKPNY Research Package: http://www.traders-choice.com/pdf?s=KKPNY

WOSYY Research Package: http://www.traders-choice.com/pdf?s=WOSYY

DRGDF Research Package: http://www.traders-choice.com/pdf?s=DRGDF

============

Highlights from today’s reports include:

On Monday, March 14, 2016, NASDAQ Composite ended at 4,750.28, up 0.04%, Dow Jones Industrial Average advanced 0.09% to finish the day at 17,229.13 and the S&P 500 closed at 2,019.64, down 0.13%.

– Amarantus Bioscience Holdings Inc.’s stock edged lower by 6.25% to close Monday’s session at USD 0.11. The company’s shares oscillated between USD 0.10 and USD 0.13. The stock recorded a trading volume of 1.73 million shares, which was above its 50-day daily average volume of 1.34 million shares and its 52-week average volume of 0.42 million shares. Over the last three days Amarantus Bioscience Holdings Inc.’s shares have advanced 1.94% while in the past one week the stock has moved down 15.32%. Furthermore, over the last three months the stock has lost 76.67% and in the past six months the shares have shed 95.16%. Additionally, the stock is trading below its 50-day and 200-day moving averages of USD 0.19 and USD 0.72, respectively. Besides, the stock has a negative beta of 1.23.

– The stock of Koninklijke KPN NV gained 0.38% to close Monday’s session at USD 3.99. The shares of the company moved in the range of USD 3.99 and USD 4.03. A trading volume of 0.25 million shares was recorded, which was slightly lower than its 150-day daily average volume of 0.26 million shares and its 52-week average volume of 0.29 million shares. Over the last five days Koninklijke KPN NV’s shares have advanced 3.77% and in the past one month the stock has gained a momentum of 7.39%. Additionally, over the last three months the stock has advanced 7.39% and in the past six months the shares have registered a gain of 8.27%. Koninklijke KPN NV has a current dividend yield of 3.77%. Further, the stock has a beta of 0.49.

– Wolseley PLC’s stock increased by 0.09% to close Monday’s session at USD 5.48. The company’s shares fluctuated in the range of USD 5.47 and USD 5.51. A total of 0.09 million shares exchanged hands, which was lesser than its 50-day daily average volume of 0.26 million shares and its 52-week average volume of 0.16 million shares. Over the last three days Wolseley PLC’s shares have advanced 0.64% while in the past one week the stock has moved down 1.53%. Furthermore, over the last three months the stock has lost 3.10% and in the past six months the shares have shed 15.57%. Wolseley PLC has a current dividend yield of 2.52%. Further, the company is trading at a price to earnings ratio of 32.21, which compares to its historical PE ratio of 34.82.

– Detour Gold Corp.’s stock slipped by 4.78% to close Monday’s session at USD 14.70. The share price vacillated between USD 14.65 and USD 15.65. The stock recorded a trading volume of 0.04 million shares, which was below its 50-day daily average volume of 1.67 million shares but slightly above its 52-week average volume of 0.03 million shares. Over the last five days Detour Gold Corp.’s shares have declined by 7.80% while in the past one month the stock has gained a momentum of 4.35%. In addition, over the last three months the stock has gained 36.98% and year to date the shares have picked up 41.09%. The company has returned 78.22% in the past one year, on a compounded total return basis. The stock is trading at a price to book ratio of 1.42. Additionally, the stock is trading at a price to cash flow ratio of 23.90 and a price to sales ratio of 5.03.

About Trader’s Choice:

Trader’s Choice (“TC”) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. TC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

TC has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third party research service company (the “Reviewer”). The Reviewer has reviewed and revised the content, as necessary, based on sound investment judgment and publicly available information which is believed to be reliable. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer (collectively referred to as the “Production Team”) in any way. The Production Team is compensated on a fixed monthly basis and do not hold any positions of interest in any of the securities mentioned herein. The information in this release has been sourced from a third party data base.

NO WARRANTY

TC, the Author and the Reviewer (collectively referred to as the “Publishers”) are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by the Publishers whatsoever for any direct, indirect or consequential loss arising from the use of this document. The Publishers expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, the Publishers do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither TC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.traders-choice.com/.

RESTRICTIONS

TC is not available to residents of Belarus, Cuba, Canada, Iran, North Korea, Sudan, Syria or Somalia.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:
E-mail: press (at) traders-choice.com

SOURCE: Trader’s Choice

ReleaseID: 437867

DALLAS, TX / ACCESSWIRE / March 15, 2016 / Nurses Lounge, Inc, an online professional network for nurses (nurseslounge.com) and wholly-owned subsidiary of MedCAREERS Group, Inc. (MCGI or the Company) (PINKSHEETS: MCGI), a development stage company, announced today that they plan to fully staff their hiring solutions sales team over the next thirty to sixty days by adding five additional regional sales representatives to their staff as they begin transforming from a near total focus on building out their network to focusing on growing sales.

Over the past few months Nurses Lounge reports that they’ve been fine-tuning their Nurse Hiring Solutions offering to healthcare systems and believe they have proven out an early adopter sales model that can bring leading healthcare systems, big and small, onto their platform from across the country. These launch prices are much less than stand-alone job boards charge today while still being potentially able to bring the company to positive operating cash flow by the end of the second quarter by meeting only nominal sales goals.

“These are exciting times to be a shareholder in MedCAREERS Group, Inc. As we work towards achieving our goal to be the premier online network for the nursing profession, we believe that over the last few months we have created a much stronger company from the perspective of job-posting diversification, explosive growth potential, and market capitalization,” said Armes, president and CEO of MedCAREERS Group, Inc.

For more information, contact Tim Armes, CEO at 972-393-5892 or tarmes@nurseslounge.com. Visit www.nurseslounge.com; follow on Facebook at https://www.facebook.com/pages/Nurses-Lounge/38580343666 and on twitter @TheNursesLounge.

MedCAREERS Group, Inc.’s focus is to develop and build value through its wholly-owned subsidiary Nurses Lounge, Inc., an online professional network and communication resource for nurses and stakeholder organizations such as nursing schools, associations and employers. By consolidating the profession onto one simple to use network, Nurses Lounge provides the tools and resources that allows organizations a more effective way to communicate to directly to their audience and the broader nursing profession.

Forward-Looking Statements

This press release may contain forward-looking statements, including information about managements view of the Companys future expectations, plans and prospects. In particular, when used in the preceding discussion, the words “believes,” “expects,” “intends,” “plans,” “anticipates,” or “may,” and similar conditional expressions are intended to identify forward-looking statements. Any statements made in this news release other than those of historical fact, about an action, event or development, are forward-looking statements. Such statements are based upon assumptions that in the future may prove not to have been accurate and are subject to significant risks and uncertainties. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, it can give no assurance that its forward-looking statements will prove to be correct. Such statements are subject to a number of assumptions, risks and uncertainties, many of which are beyond the control of the Company. Factors that could cause results to differ include but are not limited to, successful performance of internal plans, product or services development and acceptance, the impact of competitive services and pricing, or general economic risks and uncertainties. Investors are cautioned that any forward-looking statements are not guarantees of future performance and actual results or developments may differ materially from those projected. The forward-looking statements in this press release are made as of the date hereof. The Company takes no obligation to update or correct (i) its own forward-looking statements, except as required by law, or (ii) those prepared by third parties that are not paid for by the Company.

SOURCE: MedCAREERS Group, Inc.

ReleaseID: 437847